EUCTR2005-001030-33-GBActive, not recruitingPhase 1
PATCH Prostate Adenocarcinoma: TransCutaneous HormonesA randomised-controlled trial of transcutaneous oestrogen patches versus LHRH agonists in prostate cancer. - PATCH
niversity College London0 sites2,500 target enrollmentStarted: August 16, 2005Last updated:
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 2,500
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- Male
Inclusion Criteria
- •Newly Diagnosed Patients
- •with at least one of:
- •(i)Stage T3/4 NO or NX M0 histologically confirmed prostate adenocarcinoma with either PSA=20ng/ml or Gleason sum score =6
- •(ii)Stage Tany N+ M0 or Tany Nany M+ histologically confirmed prostate adenocarcinoma
- •(iii)Multiple sclerotic bone metastases with a PSA=50ng/ml without histological confirmation of prostate cancer
- •Patients with histologically confirmed prostate adenocarcinomapreviously treated with radical surgery and/or radiotherapy who are now relapsing
- •with at least one of:
- •(i)PSA =4ng/ml and rising with doubling time less than 6 months
- •(ii)PSA =20ng/ml
- •(iii)Documented evidence of metastatic disease with PSA>4ng/ml
- •Note: Prior hormone therapy for localised disease must have been completed at least 12 months previously and have been no longer than 12 months in duration. It can have been given as adjuvant or neoadjuvant therapy.
- •Patients who have started Bicalutamide or Flutamide (up to 8 weeks prior to date of randomisation) are eligible. Patients who have started Cyproterone Acetate prior to randomisation are not eligible.
- •For all patients:
- •(i)Intention to treat with long-term androgen deprivation therapy (> 3 years).
- •(ii)Fit for all protocol treatment and follow-up, WHO performance status 0-2 (see protocol v12.0 Appendix A)
- •(iii)Should have completed the appropriate investigations prior to randomisation (see protocol v12.0 section 4.4)
- •(iv)Written informed consent
- •(v)Willing and expected to comply with protocol
- •(vi)For newly diagnosed N0M0 patients only - Intention to treat with radical radiotherapy (unless there is a specific contraindication; exemption can be sought in advance of consent after discussion with the PATCH Trial Manager).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2500
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2500
Exclusion Criteria
- •(i)Prior systemic therapy for locally advanced or metastatic prostate cancer except as listed in protocol section 4.2.
- •(ii)Any other previous or current malignant disease or Cardiovascular disease which is thought likely to compromise the patient’s ability to tolerate therapy or affect assessment.
- •(iii) Cardiovascular exclusions:
- •a. Any history of cerebral ischaemia (e.g. Stroke or TIA) within 2 years of randomisation
- •b. Any history of deep vein thrombosis or pulmonary embolism confirmed radiologically or a known thrombophilic disorder
- •(e.g. Protein C, protein S, or antithrombin deficiency)
- •c. History of myocardial infarction/acute coronary syndrome
- •(i)within the last 6 months
- •(ii)greater than 6 months with evidence of q-wave anterior infarct on ECG*1 and 2
- •d. Unstable angina (typical cardiac chest pain at rest lasting more than 15 minutes) within the last year *2.
- •e. Angina that occurs on walking 100 metres on the level or after climbing one flight of stairs at a normal pace and in normal condition, or angina that causes marked limitation of ordinary physical activity or occurs at rest*2.
- •f. Heart failure: If patients have symptoms such as shortness of breath or oedema that are attributed to heart failure and this causes marked limitation of activity and/or they are comfortable only at rest then they should be excluded from the study*2.
- •g. Pulmonary oedema on CXR.
- •(iv) Known porphyria.
- •*1 If assistance with interpretation of ECG is required and not available locally please fax ECG to PATCH Trial Manager on 020 7670 4818. Please allow two working days for a response. Any other cardiac queries can also be forwarded to the PATCH Trial Manager by telephone or email (and will be directed to the PATCH Trial Cardiologist).
- •*2 Patients that have a history of ischaemic heart disease or heart failure are required to have an ECHO or MUGA prior to randomisation. Patients with left ventricular ejection fraction =40% will be excluded from participating in the trial.
Investigators
Similar Trials
Completed
Not Applicable
Transmurale zorg Prostaatkanker, van diagnose tot en met nazorgProstate cancer, transmural care, decision aid, SDM, Follow-up care, Substitution, Family doctors or General practitioners, Prostaatkanker, Keuzehulp, Samenwerking tussen eerste lijn en tweede lijn.NL-OMON22953Initiator: Catharina Wilhelmina Hospital (CWZ)NijmegenPrimary Sponsor/Performer: Radboud University Nijmegen Medical centerOther performers: CWZ in Nijmegen, Maashospital Pantein in Boxmeer200
Active, not recruiting
Not Applicable
Hormone-refractory Prostate cancer first Line Intermittent Taxotere and Estramustine. - NDProstate cancer.MedDRA version: 6.1Level: PTClassification code 10036909EUCTR2006-005728-17-ITAZIENDA PROVINCIALE PER I SERVIZI SANITARI DELLA PROVINCIA AUTONOMA DI TRENTO128
Not yet recruiting
Not Applicable
Transperineal prostate biopsy under local anaesthetic compared to general anaesthetic for men with suspected prostate cancerCancer - ProstateProstate cancerACTRN12620001145998Monash Health Department of Urology620
Completed
Not Applicable
Transdermal androgen in patients with aqueous deficient dry eyeDry eyetransdermal androgen,androgen,androgel,aqueous deficient dry eyeTCTR20160324001Faculty of medicine20
Completed
Not Applicable
Dutasteride for biopsy-negative benign prostate hyperplasia - effects on cancer detection and aging male symptomsbiopsy-negative benign prostate hyperplasiaJPRN-UMIN000005288Department of Urology, University of Tokyo Hospital40